Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEA for Chemotherapy-Induced Neuropathy
NCT05246670Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palmitoylethanolamide in chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Academic and Community Cancer Research United. Primary endpoint: Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 at 8 weeks. Started May 2022; status: active, not recruiting.
02
Drugs
palmitoylethanolamide
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05246670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246670.